The Effect of some Variables on the Formulation of Captopril as Tablets Shaymaa Nazar Al – Sammarrai

Abstract

Captopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension,
congestive heart failure, and myocardial infraction.
The only dosage form available for captopril is the plain tablet in strength of 12.5,25,50 and 100mg
tablet.
This investigation is concerned with factors affecting the formulation of captopril as a plain
tablet dosage form of 50mg. Many trials were made to prepare satisfactory tablets for the drug by
using wet – granulation methods with various additives. It was found that poly vinyl pyrrolidone
(P.V.P.) as binder gave the most satisfactory tablets. At the same time a shorter disintegrantion time
and slower dissolution rate were obtained with the addition of starch intragranular.
While the distintegration time and dissolution rate were faster for explotab when it was used
intragranular in comparison with starch.
A comparative study on the physical properties of the prepared tablets with Capoten®
(Squibb), Miniten® (APM), and Capocard® (DAD) tablets, showed that the release of drug from the
selected formula was similar to that obtained from Miniten® at 0.1N HCl and 37C.
The stability of the prepared tablet was also studied at 50ï‚°C, 60ï‚°C, and 70ï‚°C for 4 months and
the calculated shelf – life was about 3.5years at 25C.